Literature DB >> 16166275

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy.

Leisha A Emens1, Elizabeth M Jaffee.   

Abstract

Engaging the power of the patient's own immune system to actively seek out and destroy transformed cells holds great promise for cancer therapy. Tumor vaccines offer the potential for preventing cancer in high-risk individuals, preventing disease relapse after diagnosis and initial therapy, and shifting the balance of the host-tumor interaction to mitigate the progression of advanced cancers. The therapeutic activity of tumor vaccines is limited by the sheer physical burden of the cancer itself, pathways of local immune tolerance and escape active within the tumor microenvironment, and superimposed potent systemic mechanisms of immune tolerance. In this review, we describe how cytotoxic chemotherapy can be integrated with tumor vaccines using unique doses and schedules to break down these barriers, releasing the full potential of the antitumor immune response to eradicate disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166275     DOI: 10.1158/0008-5472.CAN-05-1797

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

2.  Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.

Authors:  Michael P Gustafson; Yi Lin; Kent C New; Peggy A Bulur; Brian Patrick O'Neill; Dennis A Gastineau; Allan B Dietz
Journal:  Neuro Oncol       Date:  2010-02-23       Impact factor: 12.300

Review 3.  Development of TLR9 agonists for cancer therapy.

Authors:  Arthur M Krieg
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

4.  Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells.

Authors:  Galina V Shurin; Irina L Tourkova; Michael R Shurin
Journal:  J Immunother       Date:  2008-06       Impact factor: 4.456

Review 5.  Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Authors:  James L Gulley; Ravi A Madan; Philip M Arlen
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

6.  Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.

Authors:  Yi T Koh; Andrew Gray; Sean A Higgins; Bolyn Hubby; W Martin Kast
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

7.  Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy.

Authors:  Michael G LaCelle; Shawn M Jensen; Bernard A Fox
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

8.  Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.

Authors:  Kent A Smith; Brenna L Meisenburg; Victor L Tam; Robb R Pagarigan; Raymond Wong; Diljeet K Joea; Liz Lantzy; Mayra A Carrillo; Todd M Gross; Uriel M Malyankar; Chih-Sheng Chiang; Diane M Da Silva; Thomas M Kündig; W Martin Kast; Zhiyong Qiu; Adrian Bot
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

Review 9.  Chemotherapy remains an essential element of personalized care for persons with lung cancers.

Authors:  M D Hellmann; B T Li; J E Chaft; M G Kris
Journal:  Ann Oncol       Date:  2016-07-25       Impact factor: 32.976

10.  Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice.

Authors:  Ekaterina A Alyamkina; Evgenia V Dolgova; Anastasia S Likhacheva; Vladimir A Rogachev; Tamara E Sebeleva; Valeriy P Nikolin; Nelly A Popova; Konstantin E Orishchenko; Dmitriy N Strunkin; Elena R Chernykh; Stanislav N Zagrebelniy; Sergei S Bogachev; Mikhail A Shurdov
Journal:  Genet Vaccines Ther       Date:  2009-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.